ESALF (Eisai Co) Other Financing: $-4 Mil (TTM As of Mar. 2026)


ESALF Eisai Co Ltd ESALF
74 GF Score
Price $25.00
GF Value $35.73
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Eisai Co Other Financing?

Eisai Co ESALF 74 Other Financing is $-4 Mil as of Mar. 2026. GuruFocus rates ESALF with a GF Score™ of 74/100 and a GF Value™ of $35.73 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Eisai Co's Other Financing for the three months ended in Mar. 2026 was $3 Mil.

Eisai Co's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $-4 Mil.

Eisai Co Other Financing Historical Data

* Premium members only.

The historical data trend for Eisai Co's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eisai Co Other Financing Chart

Eisai Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.54 0.62 -3.04 -1.83 -6.94

Eisai Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 -2.93 -3.82 -0.44 3.35
ESALF
74GF Score
Eisai Co Ltd ESALF
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eisai Co Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-4 Mil mean?
Eisai Co (ESALF) has a Other Financing of $-4 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Eisai Co and its competitors.
Is Eisai Co's Other Financing too high?
Eisai Co's current Other Financing is $-4 Mil. Overall, Eisai Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's Other Financing compare to ZTS?
Eisai Co's Other Financing of $-4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Eisai Co and its competitors. Eisai Co's current Other Financing is $-4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Modestly Undervalued. The stock's GF Value™ is $35.73, compared to a current price of $25.00 — trading 30% below its estimated fair value. The current Other Financing is $-4 Mil. Eisai Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Eisai Co (ESALF), the current Other Financing is $-4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eisai Co (ESALF) Overvalued in 2026?

Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued. The current stock price of $25.00 is trading 30% below its estimated GF Value™ of $35.73. GuruFocus considers Eisai Co to be Modestly Undervalued.

Key valuation signals for ESALF:

  • Other Financing: $-4 Mil
  • GF Value™: $35.73 vs. price of $25.00 (30% below fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eisai Co Business Description

Address 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
74GF Score

Get the complete analysis for ESALF

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.00
Price
$35.73
GF Value